We take an evidence-based approach to GLP-1 drugs, working with our partners to develop individualized strategies that promote clinically appropriate use and consider total cost of care, long-term value and member health outcomes.


The impact of GLP-1s

Glucagon-like peptide-1 agonists, or GLP-1s, have historically been used to manage type 2 diabetes. But there has also been a substantial increase in people using these drugs for weight loss, causing demand to skyrocket. In a recent study, Prime Therapeutics and Magellan Rx found only 27% of individuals were still using GLP-1s for weight loss a year after they began treatment – and revealed increased health care costs of $7,727 per person.1 As GLP-1s continue to transform the health care landscape, we offer clinical experts who help our partners stay on the forefront of this dynamic trend, delivering trusted, evidence-based insights.


The evolution of GLP-1s

When we look at historical utilization and spend patterns, we forecast that increasing GLP-1 use for weight loss by just 1% of an insured population would drive more than an additional $10 in costs PMPM, totaling 5% of a self-insured employer’s drug spend.² So it’s clear that having a strong GLP-1 strategy is an essential element of a successful pharmacy benefits program. You can learn more about the latest GLP-1 trends, the drug pipeline and ways to capitalize on new opportunities.


Hear from our GLP-1 experts

Stay on top of the latest news

Regular updates from our newsroom


April 19, 2024

LISTEN NOW: Live at AMCP Annual 2024 – Digging into managed care pharmacy insights | Pharmacy Friends podcast

In this episode, Prime/MRx clinicians — along with special guests — discuss the hottest topics covered at the Academy of Managed Care Pharmacy (AMCP)’s 2024 Annual Meeting in New Orleans

In the news

April 16, 2024

Prime Study Finds Lower Adherence, Higher Costs for Weight Loss Drugs | AMCP 2024

Managed Healthcare Executive: Use of GLP-1 drugs and weight-loss care management programs need to focus on adherence and persistency for better health outcomes, suggests Prime Therapeutics/MagellanRx Management poster at AMCP 2024


April 15, 2024

Catch Prime Therapeutics at 2024 AMCP Annual Meeting this week 👋

Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting gathers thousands of health plan, pharmacy benefit management and biopharmaceutical experts to help define the future of managed care pharmacy

1 Internal analysis, 2023

2 Internal analysis, 2023, based on GLP-1 list prices at time of publishing, including but not limited to Wegovy and Zepbound